TORNTPHARM Intraday Analysis...

TORNTPHARM Share Price

Open 1275.00 Change Price %
High 1302.00 1 Day 31.20 2.47
Low 1274.55 1 Week 42.35 3.39
Close 1291.85 1 Month -1.00 -0.08
Volume 244669 1 Year -42.95 -3.22
52 Week High 1769.50
52 Week Low 1194.10
TORNTPHARM Important Levels
Resistance 2 1317.30
Resistance 1 1306.81
Pivot 1289.47
Support 1 1276.89
Support 2 1266.40
NSE INDIA Most Active Stocks
JPASSOCIAT 15.05 0.67%
GMRINFRA 15.45 7.67%
JINDALSTEL 100.15 7.69%
MARKSANS 48.60 20.00%
UNITECH 5.95 0.85%
RCOM 34.65 4.52%
IDEA 108.45 2.41%
FEDERALBNK 85.95 3.06%
SOUTHBANK 20.70 3.50%
JPPOWER 6.15 4.24%
More..
NSE INDIA Top Gainers Stocks
MARKSANS 48.60 20.00%
GOLDTECH 9.75 19.63%
PANACEABIO 158.35 19.33%
AUSTRAL 0.35 16.67%
IL&FSENGG 64.10 16.33%
DHARSUGAR 34.90 15.75%
UMANGDAIRY 84.45 14.59%
KAMATHOTEL 39.45 10.66%
VISASTEEL 22.45 10.59%
PEARLPOLY 30.45 10.53%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.10 -33.33%
VKSPL 0.10 -33.33%
HOTELRUGBY 4.00 -18.37%
LLOYDELENG 273.20 -16.59%
FCSSOFT 0.30 -14.29%
BLUECHIP 0.35 -12.50%
SRGINFOTEC 0.35 -12.50%
XLENERGY 2.85 -9.52%
ADHUNIK 7.85 -8.72%
GUJNREDVR 2.10 -8.70%
More..

Torrent Pharmaceuticals Limited (NSE: TORNTPHARM)

TORNTPHARM Technical Analysis 4
As on 20th Feb 2017 TORNTPHARM Share Price closed @ 1291.85 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1414.05 & Sell for SHORT-TERM with Stoploss of 1306.48 we also expect STOCK to react on Following IMPORTANT LEVELS.
TORNTPHARM Target for February
1st Target up-side 1360.42
2nd Target up-side 1402.8
3rd Target up-side 1445.18
1st Target down-side 1239.48
2nd Target down-side 1197.1
3rd Target down-side 1154.72
TORNTPHARM Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 51.75 Sideways
MFI (14) MFI is 37.96 Sideways
CCI (20) CCI is 33.99 Sideways
WILLIAM %R (14) William %R is -44.05 Sideways
ADX (14) ADX is 13.08 Range Bound
PSAR Stoploss For Short Sell 1305.90
10 Day Avg Volume Traded 13.49 % More then 10 Day Average Volume
TORNTPHARM Other Details
Segment EQ
Market Capital 16629527552.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.torrentpharma.com
TORNTPHARM Address
TORNTPHARM
Off. Ashram Road
Ahmedabad, 380009
India
Phone: 91 79 2658 5090
Fax: 91 79 2658 2100
Interactive Technical Analysis Chart Torrent Pharmaceuticals Limited ( TORNTPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Torrent Pharmaceuticals Limited
TORNTPHARM Business Profile
Torrent Pharmaceuticals Limited, a pharmaceutical company, engages in the manufacture and sale of branded and unbranded generic pharmaceutical products. The company offers its products primarily in cardiovascular, central nervous system, gastro-intestinal, diabetology, anti-infective, and pain management therapeutic areas. It offers products in the form of tablets, capsules, and parenterals. The company’s active pharmaceutical ingredients comprise nicorandil, risperidone, venlafaxine hydrochloride, ropinarole hydrochloride, duloxetine hydrochloride, ormeloxifen hydrochloride, nebivolol hydrochloride, lamotrigine, sertraline hydrochloride, and clopidogrel bisulphate; and level 1 area products include atomoxatine hydrochloride, rivastigmine hydrogen tartrate, and esomeprazole sodium. It is also involved in the provision of contract manufacturing services primarily for human insulin. Torrent Pharmaceuticals Limited primarily sells its products in India, the United States, Brazil, Europe, Russia, the Asia Pacific, Africa, and CIS countries. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. Torrent Pharmaceuticals Limited was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Ltd operates as a subsidiary of Torrent Private Limited.